Medical Condition News

RSS

Study reveals anti-diabetic properties of cashew seed extract

Cashew seed extract shows promise as an effective anti-diabetic, according to a new study from the University of Montreal (Canada) and the Universit- de Yaound- (Cameroun). Published in the journal Molecular Nutrition & Food Research, the investigation analyzed the reputed health benefits of cashew tree products on diabetes, notably whether cashew extracts could improve the body's response to its own insulin.

15 Jul 2010

New myopia control technology for eye health benefits from Vision CRC

Scientists from the Vision Cooperative Research Centre in Australia have announced that myopia, or short-sightedness, can be controlled with new technology. This ground breaking discovery was based on research conducted by Vision CRC partners – the University of Houston College of Optometry and the Brien Holden Vision Institute, located at the University of New South Wales.

15 Jul 2010

Keck School of Medicine receives grant for research on biomarker impact on breast cancer screening

Researchers at the Keck School of Medicine of the University of Southern California (USC) will test whether a set of blood-based biomarkers can assist mammography in the early detection of breast cancer with a $180,000 grant announced today from Susan G. Komen for the Cure®. The grant will fund research into whether specific biomarkers, or minute substances in the blood, can effectively distinguish breast cancer patients from their healthy counterparts and whether an inexpensive, less invasive screening strategy can be developed based on this approach.

15 Jul 2010

Hospital for Special Surgery named top hospital for orthopedics

Hospital for Special Surgery has been named the top hospital in the nation for orthopedics by U.S. News & World Report in its 2010 "America's Best Hospitals" issue. Once again the hospital ranked as a leader in rheumatology at number 3 in the nation. In addition, neurology was ranked at number 16.

15 Jul 2010

GSK confirms FDA advisory committees' vote to allow Avandia to remain on the market

GlaxoSmithKline confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the current label, to revising the label with additional warnings and restrictions to withdrawal from the U.S. market.

15 Jul 2010

Study links obesity to poorer memory, brain function in older women

The more an older woman weighs, the worse her memory, according to new research from Northwestern Medicine. The effect is more pronounced in women who carry excess weight around their hips, known as pear shapes, than women who carry it around their waists, called apple shapes.

15 Jul 2010

Enrollment complete in Nabi's first NicVAX Phase III clinical trial for nicotine addiction

Nabi Biopharmaceuticals announced today that it has completed enrollment in the first Phase III clinical trial of NicVAX® (Nicotine Conjugate Vaccine), the company's innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse.

15 Jul 2010

Mylan subsidiary receives FDA final approval for Nabumetone Tablets ANDA

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nabumetone Tablets USP, 500 mg and 750 mg.

15 Jul 2010

KRX-0401 receives Orphan Drug designation from FDA for treatment of neuroblastoma

Keryx Biopharmaceuticals, Inc. today announced that KRX-0401 (perifosine) has received Orphan Drug designation from the U.S. Food and Drug Administration for the treatment of neuroblastoma, a cancer of the nervous system affecting mostly children and infants for which there are no FDA approved therapies.

15 Jul 2010

SWCRF/Emerald Foundation Global Collaborative Grant to fund critical cancer research

The leukemia stem cell-the root cause of all acute leukemias- represents a small population of cells in patients that are difficult to eliminate with standard treatments available today. Though current chemotherapy can produce temporary remission in leukemia survivors, they remain at risk of experiencing a recurrence and dying from the disease.

15 Jul 2010

Concert Medical releases 'Conductor' family of Interventional Coronary Guidewires in U.S.

Concert Medical, LLC today announced the launch of the "Conductor™" family of Interventional Coronary Guidewires to the U.S. market. These guidewires are designed to address an extensive range of coronary disease cases at a superior value. The FDA granted Concert Medical clearance for the use and sale in the U.S. of the Conductor product line in September 2009.

15 Jul 2010

Research: Early diagnosis, care management for people with dementia can lower outpatient costs by 30%

Early detection, diagnosis and care management for people newly diagnosed with cognitive impairment and dementia reduces outpatient costs by almost 30 percent, according to new research reported today at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 in Honolulu.

15 Jul 2010

Aeterna Zentaris' partner Keryx receives FDA orphan-drug designation for perifosine in neuroblastoma

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, Inc., has been granted orphan-drug designation by the U.S. Food and Drug Administration for perifosine, Aeterna Zentaris' novel, potentially first-in-class, oral Akt inhibitor, for the treatment of neuroblastoma.

15 Jul 2010

Aestus, Eisai collaborate to research and develop novel therapeutics for psychiatric disorders

Aestus Therapeutics, Inc. announced today a collaboration agreement with Eisai Inc. on research and development of novel therapeutics for the treatment of psychiatric disorders. The multi-year collaboration will entail pre-clinical validation of potential therapeutics leading to clinical proof-of-concept studies.

15 Jul 2010

Amorfix grants Biogen Idec exclusive worldwide rights to lead ALS monoclonal antibodies

Amorfix Life Sciences Ltd. today announced that it has entered into a licensing agreement granting Biogen Idec exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis (ALS) monoclonal antibodies. The antibodies have shown efficacy in animal models of ALS and Biogen Idec will now, at its expense, complete the development and prepare for clinical trials.

15 Jul 2010

Aastrom commences extension study for control patients from Phase 2 IMPACT-DCM clinical trial

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced the initiation of an extension study for control patients from the company's ongoing open-label Phase 2 IMPACT-DCM clinical trial in patients with dilated cardiomyopathy (DCM).

14 Jul 2010

Research provides better understanding of drugs used to treat, prevent cardiovascular disease

Using chemical labeling and mass spectrometry-based techniques, Mark Chance, PhD, director of the Case Western Reserve University School of Medicine Center for Proteomics and Bioinformatics and professor of physiology and biophysics; Sayan Gupta, PhD, instructor at the Case Center for Proteomics and Bioinformatics; and a research team from the University of Oxford, for the first time, were able to take a high resolution picture of the open state of a K+ channel, allowing them to comparatively analyze gating mechanisms important to heart function and nerve signaling - in addition these techniques have already permitted Case Western investigators to gain a deeper understanding of G-protein coupled receptors.

14 Jul 2010

Diet and exercise can reduce severity of hot flashes in overweight, obese women

A new study shows that overweight and obese women who suffer from hot flashes can reduce the severity of their hot flashes if they lose weight through diet or exercise.

14 Jul 2010

Summer campaign to combat crimes against fashion, dangerous sunburn

FASHION-LOVING Brits have denounced 'socks and sandals' as the ultimate summer fashion faux pas, in a poll released today (13th July) to celebrate the launch of 'Fashion Forecast' from Cancer Research UK's SunSmart campaign and fashion retailer ASOS.com, which provides tailored online fashion advice to help people be stylish while avoiding sunburn this summer.

14 Jul 2010

Media outlets focus on audiences towards Alzheimer's disease: Intellect Neurosciences

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease, today announced that it is pleased with the recent press coverage the Company and Dr. Daniel G. Chain, Ph.D., the Company's Chairman and Chief Executive Officer, recently has received.

14 Jul 2010

Medical Condition News

Study reveals anti-diabetic properties of cashew seed extract

New myopia control technology for eye health benefits from Vision CRC

Keck School of Medicine receives grant for research on biomarker impact on breast cancer screening

Hospital for Special Surgery named top hospital for orthopedics

GSK confirms FDA advisory committees' vote to allow Avandia to remain on the market

Study links obesity to poorer memory, brain function in older women

Enrollment complete in Nabi's first NicVAX Phase III clinical trial for nicotine addiction

Mylan subsidiary receives FDA final approval for Nabumetone Tablets ANDA

KRX-0401 receives Orphan Drug designation from FDA for treatment of neuroblastoma

SWCRF/Emerald Foundation Global Collaborative Grant to fund critical cancer research

Concert Medical releases 'Conductor' family of Interventional Coronary Guidewires in U.S.

Research: Early diagnosis, care management for people with dementia can lower outpatient costs by 30%

Aeterna Zentaris' partner Keryx receives FDA orphan-drug designation for perifosine in neuroblastoma

Aestus, Eisai collaborate to research and develop novel therapeutics for psychiatric disorders

Amorfix grants Biogen Idec exclusive worldwide rights to lead ALS monoclonal antibodies

Aastrom commences extension study for control patients from Phase 2 IMPACT-DCM clinical trial

Research provides better understanding of drugs used to treat, prevent cardiovascular disease

Diet and exercise can reduce severity of hot flashes in overweight, obese women

Summer campaign to combat crimes against fashion, dangerous sunburn

Media outlets focus on audiences towards Alzheimer's disease: Intellect Neurosciences

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News